Comparison of efficacy of Dorzolamide 2% timolol 0.5% fixed combination versus brinzolamide 1 percent brimonidine 0.2 percent fixed combination therapy in patients of primary open angle glaucoma
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 11, Pages 5988-5992
AbstractBackground: The glaucomas are a group of optic neuropathies characterized by progressivedegeneration of retinal ganglion cells. These are central nervous system neurons that have their cell bodies in the inner retina and axons in the optic nerve. The purpose of this study was to compare the efficiency of the new brinzolamide/brimonidine fixed combination vs the dorzolamide/timolol fixed combination. Materials & methods: This was randomized, open label, comparative, parallel group study to be conducted on 40 patients of POAG. Patients selected were then be randomised into two groups of 20 each as follows: Group 1 in which fixed drug combination of Dorzolamide2%/ Timolol 0.5% (DTFC) dosed twice daily and Group 2 in which fixed drug combination of Brinzolamide 1%/ Brimonidine 0.2% (BBFC) dosed twice daily. Patients were then being called for follow up and IOP were recorded. IOP readings were taken from the study eye at each visit. All the results were analyzed by SPSS software. Results: Mean IOP among patients of Group 1 at visit 1, visit 2, visit 3 and visit 4 was 28.69,
19.36, 18.46 and 17.11 mm of Hg respectively. Mean IOP among patients of Group 2 at visit 1, visit 2, visit 3 and visit 4 was 27.15, 19.12, 18.69 and 17.96 mm of Hg respectively. Nonsignificant results were obtained while comparing the mean IOP at different time intervals in between the two study groups. Conclusion: Both the modalities are equally good in treating patients with primary open angle glaucoma.
- Article View: 108
- PDF Download: 128